Sirukumab

Sirukumab (INN, USAN) (developmental code name CNTO-136) is a human monoclonal antibody designed for the treatment of rheumatoid arthritis.[1] It acts against the proinflammatory cytokine Interleukin 6 (IL-6).

Sirukumab
Monoclonal antibody
TypeWhole antibody
SourceHuman
TargetIL6
Clinical data
ATC code
Identifiers
CAS Number
DrugBank
ChemSpider
  • none
UNII
KEGG
Chemical and physical data
FormulaC6450H9926N1690O1998S46
Molar mass144588.95 g·mol−1
 NY (what is this?)  (verify)

Sirukumab is currently under development by Johnson & Johnson's subsidiary Centocor[2]

Clinical trials

Rheumatoid arthritis

It has started clinical trials.[3] and reported some phase II results.[2]

In December 2015 three phase III trials (SIRROUND-D, -H and -T) were collecting data.[4] By Feb 2017 SIRROUND-D was considered to have met both co-primary endpoints.[5]

Other

The drug is currently in phase II clinical trials for the treatment of depression.[6]

See also

References



This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.